Bristol Myers Squibb (BMY) Income from Continuing Operations (2009 - 2026)
Bristol Myers Squibb (BMY) reported Income from Continuing Operations of 2679000000.0 for Q1 2026, up 8.81% year-over-year from 2462000000.0 in Q1 2025, and up 146.69% on a QoQ basis from 1086000000.0 in Q4 2025.
Bristol Myers Squibb (BMY) has 18 years of Income from Continuing Operations data on file, last reported at 2679000000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 8.81% year-over-year to 2679000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7273000000.0 (up 33.77% YoY) and the FY2025 annual result came in at 7056000000.0, up 178.99% from the prior year.
- Income from Continuing Operations grew to 2679000000.0 in Q1 2026 per BMY's latest filing, from 1086000000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 2679000000.0 in Q1 2026 and bottomed at 11908000000.0 in Q1 2024.
- The 5-year median for Income from Continuing Operations is 1684000000.0 (2024), against an average of 893352941.18.
- The widest annual swing landed in 2024, when Income from Continuing Operations tumbled 625.28%; it then jumped 1328.95% in 2025.
- Tracing BMY's Income from Continuing Operations over 5 years: stood at 2025000000.0 in 2022, then decreased by 12.99% to 1762000000.0 in 2023, then tumbled by 95.69% to 76000000.0 in 2024, then jumped by 1328.95% to 1086000000.0 in 2025, then jumped by 146.69% to 2679000000.0 in 2026.
- Per Business Quant, the three latest BMY Income from Continuing Operations figures stand at 2679000000.0 (Q1 2026), 1086000000.0 (Q4 2025), and 2195000000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 7.40 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 5.24 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 697.00 Mn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 2.71 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 2.68 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.68 Bn |
| Dec 31, 2025 | 1.09 Bn |
| Sep 30, 2025 | 2.20 Bn |
| Jun 30, 2025 | 1.31 Bn |
| Mar 31, 2025 | 2.46 Bn |
| Dec 31, 2024 | 76.00 Mn |
| Sep 30, 2024 | 1.22 Bn |
| Jun 30, 2024 | 1.68 Bn |
| Mar 31, 2024 | -11.91 Bn |
| Dec 31, 2023 | 1.76 Bn |
| Sep 30, 2023 | 1.93 Bn |
| Jun 30, 2023 | 2.08 Bn |
| Mar 31, 2023 | 2.27 Bn |
| Dec 31, 2022 | 2.03 Bn |
| Sep 30, 2022 | 1.61 Bn |
| Jun 30, 2022 | 1.43 Bn |
| Mar 31, 2022 | 1.28 Bn |
| Dec 31, 2021 | 2.37 Bn |
| Sep 30, 2021 | 1.55 Bn |
| Jun 30, 2021 | 1.06 Bn |
| Mar 31, 2021 | 2.03 Bn |
| Dec 31, 2020 | -10.03 Bn |
| Sep 30, 2020 | 1.88 Bn |
| Jun 30, 2020 | -80.00 Mn |
| Mar 31, 2020 | -766.00 Mn |
| Dec 31, 2019 | -1.06 Bn |
| Sep 30, 2019 | 1.37 Bn |
| Jun 30, 2019 | 1.44 Bn |
| Mar 31, 2019 | 1.72 Bn |
| Dec 31, 2018 | 1.16 Bn |
| Sep 30, 2018 | 1.91 Bn |
| Jun 30, 2018 | 382.00 Mn |
| Mar 31, 2018 | 1.50 Bn |
| Dec 31, 2017 | -2.33 Bn |
| Sep 30, 2017 | 856.00 Mn |
| Jun 30, 2017 | 922.00 Mn |
| Mar 31, 2017 | 1.53 Bn |
| Dec 31, 2016 | 898.00 Mn |
| Sep 30, 2016 | 1.22 Bn |
| Jun 30, 2016 | 1.19 Bn |
| Mar 31, 2016 | 1.21 Bn |
| Dec 31, 2015 | -188.00 Mn |
| Sep 30, 2015 | 730.00 Mn |
| Jun 30, 2015 | -110.00 Mn |
| Mar 31, 2015 | 1.20 Bn |
| Dec 31, 2014 | 27.00 Mn |
| Sep 30, 2014 | 732.00 Mn |
| Jun 30, 2014 | 334.00 Mn |
| Mar 31, 2014 | 936.00 Mn |
| Dec 31, 2013 | 735.00 Mn |
| Sep 30, 2013 | 692.00 Mn |
| Jun 30, 2013 | 530.00 Mn |
| Mar 31, 2013 | 623.00 Mn |
| Dec 31, 2012 | 924.00 Mn |
| Sep 30, 2012 | -713.00 Mn |
| Jun 30, 2012 | 808.00 Mn |
| Mar 31, 2012 | 1.48 Bn |
| Dec 31, 2011 | 1.23 Bn |
| Sep 30, 2011 | 1.36 Bn |
| Jun 30, 2011 | 1.31 Bn |
| Mar 31, 2011 | 1.37 Bn |
| Dec 31, 2010 | -1.40 Bn |
| Sep 30, 2010 | 1.30 Bn |
| Jun 30, 2010 | 1.27 Bn |
| Mar 31, 2010 | 1.10 Bn |
| Dec 31, 2009 | 1.13 Bn |
| Sep 30, 2009 | 1.20 Bn |
| Jun 30, 2009 | 1.17 Bn |
| Mar 31, 2009 | 920.00 Mn |